Masimo is a global medical technology company that develops and manufactures innovative noninvasive patient monitoring technologies, including medical devices and a wide array of sensors.

 
 
  • Oxygen Reserve Index (ORi™)
  • A noninvasive and continuous parameter that provides insight into a patient’s oxygen reserve
 
  • rainbow® Pulse CO-Oximetry
  • The Masimo rainbow SET™ platform has the unique ability to measure dyshemoglobins and total hemoglobin concentration.
 
 
  • CCHD Screening
  • Reliable, Accurate Screening for Critical Congenital Heart Disease (CCHD) with Masimo SET®

News & Media

 
  • December 12, 2018
  • Washington, DC
  • Masimo (NASDAQ: MASI) Founder and CEO, Joe Kiani, was honored last night at the 2018 IPO Education Foundation Awards Dinner with the first ever IP Champion Award. The Intellectual Property Owners Education Foundation, a non-profit organization devote […]
  • November 12, 2018
  • Neuchatel, Switzerland
  • Masimo (NASDAQ: MASI) announced today that a new consensus statement on postoperative anemia management was published in Anaesthesia by an international panel of clinicians specializing in patient blood management, which includes clear guidance on th […]
  • October 25, 2018
  • Irvine, California
  • Masimo (NASDAQ: MASI) announced today that RD SET™ sensors with Masimo Measure-through Motion and Low Perfusion™ SET® pulse oximetry have received FDA clearance with improved SpO2 accuracy specifications for all patients > 3 kg. RD SET single-patient […]
  • March 2, 2018
  • Masimo Personal Health
  • MightySat is for people who want to improve their health, wellness, or fitness by providing key measurements that are more accurate & not available on other health and wellness devices. […]
  • February 23, 2018
  • Patient Safety Movement
  • The Patient Safety Movement Foundation believes reaching ZERO preventable deaths in hospitals by 2020 (0X2020™) is not only the right goal, but an attainable one with the […]
  • June 4, 2018
  • 2017 Masimo Annual Report
  • 2017 Masimo Annual Report - Automating Care. Reflecting on the Past and Defining the Future. […]

Next Generation SedLine is not licensed for sale in Canada.

For professional use. See instructions for use for full prescribing information, including indications, contraindications, warnings, and precautions.

Improve Patient Outcomes and Reduce the Cost of Care.

© 2019 Masimo. All Rights Reserved.